Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-210 in Healthy Adult Volunteers
NCT07616791Phase 1Completed
- Sponsor
- Innatus Therapeutics
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of INT-210 in inflammatory bowel disease (IBD) (4 arms), sponsored by Innatus Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at Day 21, Treatment-emergent potentially clinically-significant abnormalities in safety laboratory parameters at Day 21 and 2 more. Started Sep 2025; status: completed.
02
Drugs
INT-210
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07616791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616791.